



Report July 2025

## CEO Comments

In July, our portfolio advanced 3.06%, outperforming the benchmark by 126 bps. The equity portfolio delivered +5.51% versus +1.95% for the index.

Top contributors included Medcap, Bredband2, and Coor, while Swedencare, Essity, and Take-Two Interactive were the primary detractors.

**Securitas** Q2 report reinforced confidence in their margin expansion journey toward an 8% operating margin. Our investment case was built on, among other things, the thesis that the Stanley acquisition was not as value-destructive as the market initially priced in. We saw the potential to integrate additional technology solutions into Securitas offering, alongside a strategic pivot from volume to value.

As for the fund's operations, we are preparing for H2 with, among other initiatives, a new social media campaign and the planning of an event open to the school's students.

Sincerely, Isac Svensson

## Asset Manager's Comments

July marked a dynamic month across the Nordic equity markets, with Q2 earnings season in full swing and renewed geopolitical developments shaping investor sentiment. Risk appetite appeared to strengthen slightly, supported by relatively solid corporate results, especially within large-cap industrials and technology-related names. However, volatility remained present as markets reacted to macroeconomic signals from both sides of the Atlantic.

The OMX Stockholm rose by 2% during the month, continuing its positive trajectory since year-end. Small caps lagged somewhat, reflecting more cautious positioning amid mixed forward guidance from companies. Overall, equity performance was driven more by company-specific results than broad macro trends.

Globally, investor attention was heavily focused on the U.S., where trade discussions advanced and tariffs on imported goods reached a weighted average of nearly 18%. Sweden, domestic macro indicators remained subdued. The National Institute of Economic Research's barometer indicator showed only modest improvement, while household confidence edged up for the third consecutive month.

Q2 earnings season delivered a mixed but largely resilient picture. Strong results from key Nordic industrials and financials provided some upside surprises, particularly when excluding currency effects from the weaker USD. Earnings among large-cap companies were generally better than feared, while small- and mid-caps continued to face margin pressure.

The best performers during the month were MedCap, Bredband2, and Coor, while the weakest were Swedencare, Essity, and Take-Two Interactive.

MedCap posted its strongest quarterly report ever, building on already strong share price momentum. Coor also reported a solid quarter, while Bredband2 surged following a takeover bid from Telia, offering a 35% premium. We have accepted the bid, as our original investment thesis has now played out. On the negative side, Swedencare and Essity detracted from performance due to disappointing earnings reports, while Take-Two Interactive also underperformed.

For the month of July, our portfolio returned 3.06%, outperforming the benchmark return of 1.80%, and generating 1.26 percentage points of alpha.

- Equity holdings returned 5.51%, significantly ahead of the benchmark's 1.95%, driven by strong earnings and selective positioning in high-conviction names.
- Corporate bonds underperformed their benchmark while Global bonds Outperformed.
- Alternative investments returned 2.37%, compared to the benchmark's 0.90%, with gains across multiple strategies, though these figures remain subject to a one-month NAV lag.

Altogether, July was a strong month for the portfolio. Equities led performance, supported by solid stock selection, while alternative assets continued to provide valuable diversification. As we move further into the second half of the year, we remain vigilant in monitoring macroeconomic developments and committed to maintaining a flexible, high-conviction approach to capital allocation.

Sincerely, William Balksten

3,4%

Benchmark Correlation Last 12m

0,42


0,00

DKK

0/ P		P . (P	0/ B : 0 **	0/ ~ :
		_		%Gai
			,	2707,6%
		-		643,39
				164,6%
				144,69
		Take-Two Interactive	4,4%	61,8%
				% Los
200			,	-34,89
		-	550	-13,9%
	340 470	Swedencare	2,8%	-7,6%
Coor 4,4%	338 420	SmartEye	2,4%	-4,89
		CAG	3,9%	2,79
Portfolio	Benchmark	Allocation		Weigh
3,06%	1,80%	Alternative Investments		12,9%
6,24%	24,04%	Corporate Bonds		18,1%
5,75%	0,22%	Global Bonds		12,9%
117,01%	138,44%	Money Market		8,6%
5,83%	6,56%	Equities		47,5%
164	164	Currency Exposure		1 Montl
110	113	-		88,6%
Number of Positive Months Number of Negative Months 54				5,8%
				4,1%
5.45%	8.11%			0,0%
				1,6%
0,00	0,00	Ditt		1,070
Portfolio	Benchmark	Best Performers		1 Montl
5,51%	1,95%	MedCap		46%
8,64%	34,92%	Bredband2		33%
6,93%	-0,34%	Coor		11%
524,97%	464,72%	Worst Performers		1 Montl
		Swedencare		-12%
Average Yearly Return 9,39%	-,			-8%
245	245	Take-Two Interactive		-5%
				1 Month
Number of Positive Months 145 Number of Negative Months 100		• •		78,79
	12			12,19
11 150/2	12 /150/2			0,0%
				0,09
0,46	-0,17	NOK		2.40
	Portfolio 3,06% 6,24% 5,75% 117,01% 5,83%  164 110 54  5,45% 0,73 0,00  Portfolio 5,51% 8,64% 6,93% 524,97% 9,39%  245 145	67,2%         5 112 000           10,8%         824 481           8,3%         631 837           8,2%         625 354           7,9%         603 436           7,4%         564 845           5,6%         426 929           5,2%         399 228           4,7%         357 000           4,5%         340 470           4,5%         340 470           4,4%         338 420           Portfolio Benchmark           3,06%         1,80%           6,24%         24,04%           5,75%         0,22%           117,01%         138,44%           5,83%         6,56%           164         164           110         113           54         51           5,45%         8,11%           0,73         -0,20           0,00         0,00           524,97%         464,72%           9,39%         8,85%           245         245           145         153           100         92           11,15%         12,45%	Portfolio   Value   67.2%   5.112.000   Microsoft   MedCap	Microsoft   8,3%

Report July 2025

## Equity Performance



## Portfolio Performance

